Loading clinical trials...

Risk Stratification and Early Alerting Regarding COVID-19 Hospitalization | Clinical Trials | Clareo Health

TERMINATED

Risk Stratification and Early Alerting Regarding COVID-19 Hospitalization

NCT04709068•Current Health

Summary

The purpose of this research is to remotely monitor individuals who have tested positive for COVID-19 to learn more about progression and recovery from the disease. Individuals who test positive for COVID-19 will wear the Current Health wearable device continuously and answer a brief series of questions on Current Health tablet daily for up to 30 days. The health data will be used to develop predictive models of hospitalization risk.

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Living in the United States (contiguous states)
•Aged 21 years or older
•Able to provide documentation of +Polymerase Chain Reaction (PCR) or +antigen test for COVID-19 within the past 48 hours
•Self-reports that comfortable and willing to wear the wearable device and interact with a tablet-based interface daily
•Able to provide a next of kin/designated person who can be contacted in the event of hospitalization for follow up.

Exclusion Criteria

•Under the age of 21
•Received a positive test result more than 48 hours prior to contacting study staff or has a pending test for COVID-19
•Cannot confirm a PCR or antigen positive test for COVID-19
•Is unable to read English
•Is unwilling to wear the device 24 hours/day except for showering/bathing or interact with a tablet-based interface for daily questionnaire
•Is unwilling or unable to provide baseline data required for entry into the study
•Is unable to provide a next of kin/designated person who can be contacted in the event of hospitalization for follow-up
•Heavy tattooing on both upper arms
•Known atrial fibrillation (permanent or paroxysmal)
•Has taken/is taking part in a COVID-19 vaccine or treatment trial

Locations (1)

Current Health

New York, New York, United States

Key Dates

Start Date

February 8, 2021

Primary Completion Date

May 3, 2021

Completion Date

June 1, 2021

Last Updated

September 19, 2024

Enrollment

ACTUAL participants

Conditions

Covid19

Interventions

Current Health

DEVICE

The Effect of the Covid-19 Pandemic Among Operated Patients

NCT04525716

Covid19Surgery

View study

RECRUITINGPHASE3

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

NCT03188796

Critical IllnessVitamin D Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Risk Stratification and Early Alerting Regarding COVID-19 Hospitalization

Inclusion Criteria

Exclusion Criteria

The Effect of the Covid-19 Pandemic Among Operated Patients

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Covid-19 and Influenza Oral Vaccine Study

Conversations You Want About Corona Virus Disease (COVID-19)

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy